NCT00089674COMPLETEDanonymous

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

AMG 162, Placebo

Indication / condition

AI-normalized

Prostate Cancer

Intervention

Source record

AMG 162, Placebo

Related intelligence directories

Indication directory: Prostate Cancer Modality directory: small molecule Target directory: AMG 162

Source & freshness

Source record

NCT ID

NCT00089674

Original source

ClinicalTrials.gov

Source last updated

Oct 17, 2018

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00089674

Title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Prostate Cancer

Condition normalized

Prostate Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AMG 162, Placebo

Target normalized

AMG 162, Placebo

Interventions

AMG 162, Placebo

Public preview

Source record

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00089674

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 17, 2018

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00089674

Indication

Prostate Cancer

Modality

small molecule

Target

AMG 162, Placebo

Intervention

AMG 162, Placebo

Source record